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Effects of Antirheumatic Agents on Cytokines
Pilar Barrera, Agnes M.Th, Boerbooms, Leo B.A. van de Putte,
and Jos W.M. van der Meer
A review of the literature concerning the effects of traditional antirheumatic 
drugs on cytokines and the cytokine and anticytokine approaches already used 
in the therapy of rheumatoid arthritis (RA) is presented. Many antirheumatic 
drugs are capable of cytokine modulation in vitro. Corticosteroids inhibit the 
transcription of a broad spectrum of genes including those encoding monocyte, 
T cell-derived cytokines and several hemopoietic growth factors, whereas 
drugs such as cyclosporin A and D-penicillamine interfere with T cell activation 
more specifically by suppressing interleukin 2 (IL-2) production. The in vivo 
effects of drug therapy on cytokines in RA patients are less well established. 
Gold compounds reduce circulating IL-6 levels and the expression of monocyte- 
derived cytokines, such as IL-1, tumor necrosis factor (TNF), and IL-6, in the 
rheumatoid synovium. Decreases in circulating IL-6, soluble IL-2 (slL-2R), and 
TNF receptors and in synovial fluid IL-1 levels have been reported with 
methotrexate. Reductions in circulating IL-6 and slL-2R concentrations have 
also been observed with cyclosporin and corticosteroids, whereas azathioprine 
reduces IL-6 but not $IL-2R. Studies on sulfasalazine are conflicting and the in 
vivo effects of D-penicillamine and antimalarials have not been studied yet. 
Interferon 7 therapy is not effective in RA but may prove a useful antifibrotic for 
systemic sclerosis. Colony stimulating factors improve the granulocytopenia 
associated with Felty's syndrome or drug toxicities but can induce arthritis 
flares and should be reserved to treat infectious complications. Promising 
results are being obtained with selective antagonism of TNF and IL-1 in RA, and 
combinations of anticytokine strategies with traditional antirheumatic drugs 
have been already envisaged. These should preferably be based in a broader 
knowledge of the effects of antirheumatic agents on the cytokine network. 
Semin Arthritis Rheum 25:234-253, Copyright © 1996 by W.B. Saunders Com­
pany
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T HE PHARMACOLOGICAL agents used 
in the therapy of rheumatoid arthritis 
(RA) have been traditionally subdivided into
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nonsteroidal anti-inflammatory drugs (NSAIDs), 
disease modifying or slow-acting antirheumatic 
drugs (DMARDs or SAARDs), and corticoste­
roids. All of these drugs are clinically effective 
and, according to a recent classification, can be 
denominated symptom-modifying anti-rheu­
matic drugs (SMARDs). The term disease- 
controlling antirheumatic therapy (DC-ART) is 
reserved for those SAARDs capable of modify­
ing not only clinical symptoms, but also radiologi­
cal and functional outcome1 (Fig 1). Despite 
broad experience with antirheumatic drugs, their 
mechanisms of action are only partially under­
stood. This is especially true for the SAARDs, a 
heterogeneous group that includes antimala­
rials, thiol compounds, sulfonamides, and anti­
metabolites, as well as cytotoxic and immunosup-
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Fig 1 : Schematic representation of the pathogenesis, manifestations, and therapeutic interventions in 
RA. Joint inflammation, involving processes such as homing, chemotaxis and activation of cells 
together with the proliferation of synovial tissue, pannus formation, and angiogenesis eventually result 
in irreversible destruction of cartilage, bone, and periarticular structures. Recognition of the involve­
ment of cytokines in the initiation and perpetuation of these events has prompted the introduction of 
anticytokine therapies for RA. NSAIDs, steroids, and SAARDs are SMARDs capable of alleviating the 
local and systemic manifestations of RA. Only those SAARDs that alter disease outcome should be 
considered DC-ART.
pressive agents. Many SAARDs interfere with 
cellular metabolic processes and have nonspe­
cific anti-inflammatory, immunoregulatory, and 
anti-angiogenic effects, which may contribute to 
their efficacy or toxicity, but usually do not fully 
explain their therapeutic effects.
Cytokines are a complex family of peptides 
with specific receptors that mediate intercellu­
lar communication and play a crucial role in 
immunologic and inflammatory reactions. The 
evidence implicating cytokines in the pathoge­
nesis of RA and other autoimmune diseases has 
had repercussions on the treatment of these 
disorders. It is known that several drugs, inclu­
ding SAARDs, modulate the cytokine network. 
This may be important because cytokines con­
trol the proliferation, activation, traffic, and 
homing of immunocompetent cells in the joint, 
as well as the growth and function of synovial, 
cartilage, bone, and endothelial cells. Further­
more, some circulating cytokines or cytokine 
receptors may act as markers of disease activity 
or immune activation and prove useful in moni­
toring the effects of treatment. Finally, and
more importantly, selected cytokines and anticy­
tokines are being used to treat RA, and the 
search for pharmacological agents with specific 
cytokine-suppressive properties has just begun. 
In this report, we review the modulatory proper­
ties of several SAARDs and other pharmacologi­
cal agents on the cytokine network and summa­
rize the clinical experience with cytokine and 
anticytokine strategies in the treatment of RA.
THE CYTOKINE NETWORK IN RA
A detailed review of the cytokine network is 
beyond the scope of this paper. Therefore only 
relevant aspects will be briefly mentioned. Ac­
cording to their biological effects, cytokines can 
be classified as proinflammatory or anti-inflam­
matory, fibrotic, growth and chemotactic factors 
(Table 1). Such a functional classification is an 
oversimplification because cytokines are charac­
terized by pleiotropism (one cytokine possesses 
multiple functions), overlap (several cytokines 
share similar effects), and mutual regulation. 
Nevertheless, by considering their function, bet­
ter insight into the links between cytokines and
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Table 1: Cytokines Relevant for Rheumatoid Arthritis: Functional Classification
Main Cell
Cytokine Source Function Other Effects
Interleukins and tumor necrosis factor
IL-1 and M0, many Proinflammatory Fever, anorexia, acute phase reaction
TNF a other ceils Cartilage and bone breakdown, fibroblast proliferation, adhesion 
molecule expression 
Stimulate synthesis of many other cytokines, such as IL-6, LIF, 
chemokines, growth- and colony-stimulating factors
IL-2 T cell (Th1) Immunostimulation T and B cell activation and proliferation, DTH reaction, t  CTL, NK, 
and LAK activity
IL-4 T cell (Th2) Anti-inflammatory B, T, and mast cell growth, synthesis of IgE, IgG 1 and lgG4 
t  IL-1 Ra and 1 IL-1, TNF, IL-6, IL-8, IFN-y production
IL-6 M0, many 
other cells
Proinflammatory
Anti-inflammatory
B and T cell proliferation and activation, Ig synthesis, thrombo- 
poiesis, mediates some IL-1 effects 
Acute phase reaction, synthesis of metalloproteinase inhibitors, 
feedback mechanism for IL-1 and TNF
IL-10 T cells Anti-inflammatory B cell differentiation and Ig synthesis, i  class II HLA expression 
f  IL-1 Ra and j  IL-1, TNF, IL-6, IL-8, IFN7 and IL-2 production
IL-13 T cells Anti-inflammatory iL-4—like activities
Chemokines
*
IL-8 family M0, other 
cells
Proinflammatory Chemotactic for neutrophils and T cells, neutrophil activation and 
degranulation
MCP-1 M0, other Proinflammatory Chemotactic for mononuclear ceils, monocyte activation
family cells
Growth factors
TGFß M0 , many 
other cells
Anti-inflammatory
Proinflammatory
Immunosuppressive
Matrix and collagen synthesis, 1 IL-1 and TNF and f  IL-1 Ra pro­
duction, I  IL-1 R expression 
Chemotactic for neutrophils and fibroblasts, fibroblast prolifera­
tion, angiogenesis, osteophyte formation 
|  T and B cell proliferation, J, CTL, NK and LAK activity
FGF, M0 , endo­ Proliferative Fibroblast proliferation
PDGF, thelial Profibrotic Matrix synthesis, angiogenesis
PD-ECGF, cells.
VEGF platelets,
other
Colony stimulating factors
GM-CSF M0 , many 
other cells
Proinflammatory Growth and differentiation of granulocyte and M0 progenitors in 
bone marrow 
|  expression of class II HLA and adhesion molecules 
M0 activation, phagocytosis and cytokine production, chemo­
tactic for monocytes
G-, M-CSF M0 , other 
cells
Proinflammatory Growth and differentiation of granulocyte and M0 progenitors in 
bone marrow 
Neutrophil and monocyte activation
Interferons
IFN^ y T cells Immunostimulation T, NK cell, and M0 activation, |  expression of class II HLA and 
adhesion molecules 
Antiproliferative, antifibrotic
Other
LIF T cells Proinflammatory IL-6-like activities, bone and cartilage resorption
Abbreviations: CSF, colony stimulating factor; G, granulocytes; M, macrophages; CTL, cytotoxic T lymphocytes; DTH, delayed type 
hypersensitivity; GF, growth factor; FGF, fibroblast GF; HLA, human leucocyte antigen; Ig, immunoglobulin; IFN, interferon; IL, 
interleukin; IL-1R, IL-1 receptor; IL-1Ra, IL-1 receptor antagonist; LIF, leukemia inhibitory factor; LAK, lymphokine activated killer cell; 
M0, macrophage; MCP-1, monocyte chemoattractant protein-1; MCAF, monocyte chemotactic and activating factor; NK, natural killer 
cell; PDGF, platelet-derived GF; PD-ECGF, platelet-derived endothelial cell GF; TGFp, transforming GF-0; TNF, tumor necrosis factor; 
VEGF, vascular endothelial GF.
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other processes involved in RA and their poten­
tial consequences for therapy can be gained.
Because of their systemic and local effects, 
interleukin 1 (IL-1) and tumor necrosis factor a 
(TNFa) are the prototypes of pro-inflammatory 
cytokines.2 Compelling evidence from in vitro 
studies and experimental arthritis models shows 
that tissue destruction and joint inflammation 
are independently regulated by IL-1 and TNF 
and that these mediators orchestrate the ar­
thritic process.2»3 The IL-1 “family’' consists of 
three related peptides: IL-la, which is primarily 
cell bound, IL-1(3, which is primarily secreted, 
and the IL-1 receptor antagonist (IL-IRa). 
These three molecules are each capable of 
binding to the membrane receptors, but only 
IL-la and (3 are biologically active. The IL-IRa 
occupies the receptor but does not activate 
signal transduction, and therefore it acts as a 
competitive IL-1 inhibitor.4 There are two types 
of IL-1 receptors. Type I (IL-1RI) mediates 
signalling activity and has a higher affinity for 
IL-la and IL-IRa, whereas type II (IL-1RII) is 
a decoy receptor, which lacks signalling capacity 
and has a higher affinity for IL-1 p.5 Membrane- 
bound and soluble forms of the IL-1RII decoy 
receptor and the IL-IRa together represent 
natural mechanisms for counteracting the poten­
tially toxic role of IL-1 in vivo.
TNFa and the related lymphotoxin (TNFp) 
bind to two forms of membrane receptors, type 
1 or p55 and type 2 or p75, which are active in 
signal transduction, and can be cleaved from the 
cell membrane yielding soluble forms (sTNFR). 
The sTNFRs behave as endogenous antagonists 
by binding TNFa, preventing it from attaching 
to the membrane receptors, but may also func­
tion as carrier molecules that preclude TNF 
degradation.6
IL-1, IL-IRa, and TNFa are present in the 
rheumatoid synovial membrane and can be 
detected in plasma and in synovial exudates of 
RA patients together with soluble forms of both 
TNFR and type II IL-1R. Compared with IL- 
IRa and sTNFR, the concentrations of IL-1 and 
TNF in biological fluids are low but this excess 
of antagonists may not be sufficient to block the 
activity of IL-1 and TNF completely.2
IL-1 and TNFa are arthritogenic in several 
animal models, and antagonizing their effects 
reduces the severity, or even prevents arthri­
tis.2’3 Moreover, these cytokines occupy a high 
position in the cytokine hierarchy because they 
stimulate the production of each other and of 
many proinflammatory cytokines including 
granulocyte-macrophage colony-stimulating fac­
tor (GM-CSF), IL-6, leukemia-inhibitory fac­
tor, IL -8 and other chemotactic factors.7 It is 
therefore not surprising that ongoing anticyto­
kine strategies for RA are primarily focused on 
suppressing the actions of IL-1 and TNF.
IL-6 stimulates B and T cell differentiation 
and activation, as well as immunoglobulin pro­
duction, and shares proinflammatory activities 
with IL-1, TNF, and colony stimulating factors. 
However, IL-6 is not arthritogenic, does not 
induce local prostaglandin-E2 or collagenase 
production, and is anti-inflammatory by promot­
ing the acute phase reaction, upregulating me- 
talloprotease inhibitors,7 suppressing IL-1 and 
TNF synthesis in vitro, and inducing IL-1 and 
TNF endogenous antagonists in vivo.8 More­
over, IL-6 is readily detected in biological fluids 
and may be a useful marker of disease activity.
Several other cytokines, including colony- 
stimulating and growth factors, chemotaxins, 
and the leukemia-inhibitor factor (LIF), are 
also present in the rheumatoid synovial mem­
brane and are thought to perpetuate the ongoing 
inflammation by stimulating cell recruitment 
and activation.7
In contrast to the abundance of monocyte- 
derived cytokines, T cell products are scant in 
the inflamed joint,9’10 which has led to specula­
tion about the role of T cells in RA. T helper 
cells can be divided into Thl (secreting IL-2 and 
IFN7 ) and Th2 subsets (secreting IL-4 and 
IL-5). Other cytokines such as transforming 
growth factor (B (TGF(3), IL-10, and IL-13 are 
not confined to these subsets and are also 
produced by non-T cells.11*12 IL-2 is implicated 
in the activation and proliferation of T, B, and 
natural killer (NK) cells, whereas IFN7  induces 
the expression of class II HLA and adhesion 
molecules, activates macrophages, lymphocytes, 
and NK cell activity and has antiproliferative 
and antifibrotic effects. Lymphocytes from RA 
patients defectively produce IL-2 and IFN7 and 
are hyporresponsive to IL-2, which could ac­
count for the low proliferative responses to 
mitogens and delayed type hypersensitivity in 
RA. Because of its immunostimulatory proper­
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ties, IL-2 has been used in the therapy of 
malignancies, whereas several studies have ex­
amined the effects of IL-2 inhibition13 and IFN7 
therapy in RA .14
In contrast with the low levels of IL-2, high 
concentrations of its soluble receptor (sIL-2R) 
have been detected in several autoimmune 
diseases including RA. These are considered to 
reflect lymphocyte activation and may be useful 
in monitoring disease activity.15
Finally, cytokines such as IL-4, IL-10, IL-13, 
and TGFp are considered anti-inflammatory 
because they inhibit the production of proinflam- 
matory cytokines such as IL-1 and TNF and 
upregulate their inhibitors.12,16 These anti­
inflammatory cytokines are being tested in ani­
mal models and may find therapeutic applica­
tion in human autoimmune diseases.
EFFECTS OF SAARDS AND OTHER 
ANTIRHEUMATIC DRUGS IN CYTOKINE
MODULATION
Our knowledge of the cellular and soluble 
mediators of inflammation has advanced our 
understanding of the mode of action of SAARDs 
in RA. Knowing that cytokines play a key role in 
the cascade of inflammatory responses has 
stimulated research on the effects of antirheu­
matic drugs on these mediators. Several in vitro 
studies and observations in animal models and 
in patients treated with SAARDs suggest that 
some of these agents have cytokine-modulating 
properties. The present section summarizes the 
literature on several SAARDs, corticosteroids, 
and other drugs with “cytokine suppressive” 
properties.
Antimalarials
The antimalarial agents hydroychloroquine 
(HCQ) and chloroquine (CQ) are quinoline 
derivatives that exert a variety of effects on 
immunocompetent cells. These agents accumu­
late in lysosomes, inhibit several enzymes, and 
interfere with the function of monocyte-macro­
phages, which may represent their main mode 
of action. Early studies showed that HCQ and 
CQ inhibit the cartilage degradation induced by 
IL-1.17 More recently, it was shown that thera­
peutic concentrations of HCQ suppressed the 
production of IL-1 and IL-6 by monocytes, 
probably acting at a posttranscriptional level.18’19
The effects of these drugs on TNFa production 
is more controversial, although combinations of 
HCQ with sulfasalazine inhibit IL-1 and TNF 
production synergistically,18’19 HCQ does not 
alter either IL-8 gene expression or synthesis by 
endothelial cells and monocytes20 or the produc­
tion of IL-2, IL-4, or IFN7 by T cells.18 How­
ever, the drug inhibits IL-6 synthesis by T cells, 
suggesting a selective effect of HCQ on some 
proinflammatory cytokines (IL-1 and IL-6).18 
The effects of HCQ therapy on cytokines in RA 
have not been investigated, but Wallace et al21 
observed lower circulating concentrations of 
IL-6 and sIL-2R in systemic lupus erythematsus 
(SLE) patients treated with HCQ than in those 
receiving only corticosteroids or no therapy. In 
a prospective study by the same authors, signifi­
cant decreases in serum IL-6 levels occurred 
after 6 and 12 weeks of treatment with HCQ, 
though sIL-2R concentrations remained un­
changed.22 This seems to confirm the relative 
lack of effect of HCQ on T cell activation.
CQ and HCQ have similar effects on mono­
cytes, although the former may have additional 
effects on T cells. CQ inhibits monocyte produc­
tion of IL-1,23 TNFa, and IL-624 and acts syner­
gistically with cyclosporin in suppressing IFN7 
production by T cells.25 CQ therapy does not 
affect IL-1 production in animal models of 
adjuvant arthritis26 or haemorrhagic shock but 
inhibits TNF, IL-6 and prostaglandin release in 
the latter.27
Gold Compounds
Gold compounds modulate the functional 
activities of virtually every immunocompetent 
cell, but inhibition of mononuclear phagocyte 
function may be of paramount importance. This 
is supported by the suppressive action of these 
agents on the production or activity of monocyte- 
derived proinflammatory cytokines.
Most in vitro studies have shown that gold 
sodium thiomalate (GST) and auranofin (AF) 
inhibit the synthesis of IL-1 by monocytes28'32 
and act synergistically when combined.19 Gold 
compounds also antagonize some of the biologi­
cal effects of IL-1,28»33’34 and therapy with these 
agents decreases IL-1 production in adjuvant 
arthritis.26,35 Danis et al studied the production 
of IL-1 by monocytes from RA patients treated 
with GST. Patients considered “high IL-1 pro-
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ducers” at baseline had transient clinical im­
provement associated with decreases in IL-1 
secretion, whereas “low producers” had a bet­
ter clinical response and an increase in IL-1 
secretion during therapy.36 The authors sug­
gested that IL-1 production before treatment 
might be predictive of the clinical response to 
GST, but several confounding factors, including 
the use concomitant medications, render this 
study inconclusive.
Gold does not alter IL-IRa synthesis by 
normal monocytes32 although increases have 
been reported in patients with RA.37 Further 
studies should elucidate whether gold therapy 
induces a beneficial shift in the IL-1/IL-lRa 
balance.
Gold compounds may modulate other proin- 
flammatory cytokines besides IL-1. GST inhib­
its the production of IL-6, but not of TNF, by 
monocytes,32 suppresses the synthesis of IL-8 
and monocyte chemoattractant protein (MCP-1) 
by rheumatoid synoviocytes,38 and interferes 
with the production of IL-8 by monocytes and 
endothelial cells.20»39 AF, however, inhibits the 
production of TNFa by monocytes,40 and sev­
eral effects of this cytokine on neutrophils.41,42 
Serial studies in patients with RA receiving 
chrysotherapy have reported reductions in circu­
lating IL-6 levels,43»44 monocyte production of 
IL-6,45 and, interestingly, cytokine expression in 
the synovial membrane as recently demon­
strated by Yanni et a l46 Using sequential syno­
vial biopsies, the authors observed a striking 
decrease in the expression of monocyte-derived 
cytokines, including IL-1 (3, IL-la, IL-6, and 
TNFa, and in the number of infiltrating mono­
cytes and macrophages after 12 weeks of treat­
ment with GST, whereas the number of T and B 
cells remained unchanged.46 Whether such re­
duction in monocyte infiltration results from 
systemic effects, like inhibition of myelopoi- 
esis,47 or from a local action of gold is unknown, 
but these results indicate that the monocyte- 
macrophage is the principal target cell for gold 
compounds. Nevertheless, T cell proliferation 
and activation and cytokine production are also 
affected by these drugs at least in vitro. Gold 
compounds inhibit T cell proliferation induced 
by mitogens, antigens,48»49 and IL-250’51 and sup­
press the synthesis of IL-2 and the expression 
and release of IL-2R by activated T cells at a
transcriptional level.49 Some of these effects 
may require low intracellular glutathione con­
centrations.52 The effect of gold on IFN*y produc­
tion is controversial,53»54 but GST inhibits sev­
eral IFNy activities such as the induction of 
class II HLA expression in monocytes55 and 
endothelial cells.51 This, together with the inhi­
bition of endothelial cell proliferation56 and 
expression of adhesion molecules by gold com­
pounds,57 may result in decreased angiogenesis 
and cell recruitment in the joint.
Chrysotherapy normalizes depressed IL-2 pro­
duction in adjuvant arthritis35 and patients with 
pemphigus vulgaris.58 In contrast, circulating 
sIL-2R levels in RA remain unchanged after 24 
weeks of gold therapy, despite clinical improve­
ment,59*61 and only one study reported lower 
sIL-2R levels in patients with clinical remission 
than in those with active disease after prolonged 
treatment.60 It seems, therefore, that despite 
the inhibitory effects of gold on T cells in vitro, 
chrysotherapy for RA does not affect T cell 
infiltration in the joint46 or lymphocyte activa­
tion evidenced by sIL-2R, at least in the short 
term.
D-Penicillamine
D-penicillamine and the related drug bucilla- 
mine, are structural analogues of cysteine, which, 
in contrast to gold and antimalarials, may pre­
dominantly affect lymphocytes (especially T 
helper cells) without altering macrophage func­
tion. Whether therapy with these drugs results 
in cytokine modulation in RA has not been 
assessed, but available in vitro studies corrobo­
rate this hypothesis.
The drugs’ effect on T cell function is medi­
ated by their capacity to generate hydrogen 
peroxide in the presence of copper salts. This 
results in a direct inhibition of T cell activation 
and production of IFNy and IL-2, and indirectly 
in decreased immunoglobulin synthesis by B 
lymphocytes.62,63
Initial in vitro studies suggested that d- 
penicillamine might decrease the production of 
monocyte products with IL-l-like activity.64 Later 
it was shown that IL-1 synthesis and bioactivity 
are suppressed only with high concentrations of 
the drug33; however, therapeutic concentrations 
do not alter the production of either IL-123»30»65 
or TNF19 by human monocytes. Moreover,
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therapy with D-penicillamine does not inhibit 
IL-1 production in the adjuvant arthritis 
model.26’66 D -p en ic illam ine  blocks the binding of 
IL-ip to a-2-macroglobulin, an acute phase 
protein that may function as carrier for IL-1 and 
other cytokines.67 This dissociating effect is not 
specific for IL-1,68 and its relevance for the 
therapeutic effect of the drug is speculative. In 
the presence of copper, D-penicillamine and 
other thiol compounds inhibit spontaneous and 
IL-l-induced fibroblast proliferation. This is 
due to the production of hydrogen peroxide 
rather than suppression of IL-1 synthesis.69 
D-penicillamine inhibits the proliferation and 
IL-8 gene expression and synthesis by endothe­
lial cells,20 and decreases neovascularization in 
vivo.70 These antiangiogenic and antifibrotic 
properties may be important for therapeutic 
efficacy in RA and systemic sclerosis. It has 
been suggested that bucillamine is superior to 
D -pen ic illam ine  in treating RA ,71 possibly be­
cause of its additional immunosuppressive ef­
fects. In vitro, both drugs inhibit T cell function, 
including IL-2 and IFN7 production, in the 
presence of copper,72 but only bucillamine forms 
an intramolecular disulphide and inhibits B cell 
function whether or not copper salts are pre­
sent.62’72 This effect is not due to decreased IL-6 
production by B ce lls .62 Furthermore bucilla­
m in e-, like D -pen ic illam ine , does not affect IL-1 
production by human monocytes.30’65
Sulfasalazine
Sulfasalazine is an azo compound of sulfapyri- 
dine and 5-aminosalicylic acid. Sulfapyridine 
seems to be the active component in RA, 
though sulfasalazine itself might also have anti- 
rheumatic properties. The exact mechanism of 
action of this drug remains also unclear despite 
its multiple anti-inflammatory and immunoregu- 
latory effects.
In vitro, sulfasalazine inhibits the production 
of IL-ip and TNFa by monocytes19’30'73-75 and 
may suppress the binding of TNFct to its recep­
tors.76 Neither the production45’74,77 nor the 
activity of IL-6 are markedly altered by sulfasala­
zine.78 However, the drug down-regulates the 
synthesis of IL-2 and IFN7 by T cells,79,80 which 
may explain its inhibitory effect on lymphocyte 
proliferation and antibody production. More­
over, sulfasalazine inhibits the proliferation as
well as IL-8 gene expression and synthesis20 in 
endothelial cells, which may account for its 
antiangiogenic effects. Interestingly, most of the 
effects of sulfasalazine on cytokines and immu- 
noregulation are not shared by its metabolites, 
which suggests that the parent compound pos­
sesses therapeutic effects.
Studies on the effect of sulfasalazine therapy 
on circulating cytokines in RA have yielded 
conflicting results. In a 6-month, placebo- 
controlled study, Danis et al77 observed 
decreases in IL-1 a, IL-1 (3, and TNFa but 
unchanged IL-6 concentrations during sulfasala­
zine therapy,77 whereas other authors reported 
no changes in IL-1 (3 and TNFa levels81 and 
decreases in serum concentrations and mono­
cyte production of IL-6.45,81*82 Circulating sIL-2R 
concentrations did not change after 12 weeks of 
therapy with sulfasalazine in several stud­
ies.61’81*82 The number of patients in these stud­
ies generally were too small to draw definitive 
conclusions and the effects of sulfasalazine 
therapy need further investigation.
Combinations of SAARDs are increasingly 
used to treat RA and there are in vitro data 
suggesting that some of these combinations 
suppress cytokine production in a synergistic 
manner,19 In an open study conducted in our 
center, the combination of sulfasalazine with 
methotrexate proved clinically superior to 
methotrexate alone.83 Serial cytokine measure­
ments showed decreases in IL-6 and sIL-2R 
levels with both therapies, but the concentra­
tions of sTNFR and the production of IL-1 (3 
and IL-IRa by monocytes fell only in patients 
treated additionally with sulfasalazine. These 
results suggest an additional or specific sulfasala­
zine on these cytokines84 and encourage further 
studies on the effects of other SAARD combina­
tions.
Methotrexate
Intensive efforts have been made to elucidate 
the mechanism of action of methotrexate. Be­
cause of its antifolate effect, methotrexate may 
impair DNA, RNA, and protein synthesis, in­
hibit transmethylation reactions and polyamine 
synthesis, and stimulate adenosine release. 
Moreover, the drug can inhibit 5-lipoxygenase 
activity and has modulatory effects on cyto­
kines.85
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Methotrexate inhibits some biological activi­
ties of IL-1 including the proliferation of thymo­
cytes86’87 and synovial fibroblasts but does not 
affect the production of collagenase, prostaglan­
din E, hyaluronic acid, or metalloprotease inhibi­
tors induced by IL-1.88’89 This suggests that the 
drug antagonizes the proliferative but not the 
secretory activities of IL-1.88 The suppression of 
IL-1 bioactivity by methotrexate is due to its 
antifolate effect because it can be reversed by 
folinic acid,87 although binding of methotrexate 
to IL-1, which has structural homology to dihy­
drofolate reductase (DHFR), or receptor down- 
regulation have been also proposed to explain 
this effect.90 Methotrexate therapy decreases 
the production of IL-1 in adjuvant arthritis,91'93 
although this has not been consistently observed 
in RA. Two studies have assessed the effect of a 
single dose of methotrexate on monocyte IL-1 (3 
production: Segal et al86 reported no changes in 
9 patients treated with methotrexate for vari­
able periods of time, whereas we observed 
significant decreases after the first methotrexate 
dose, but not in patients treated for longer than
1 year who already had lower IL-1|3 production 
and less active disease.94 In another study, 
Chang et al95 reported decreases in IL-1 produc­
tion in 4 of 8 patients after 6 weeks of methotrex­
ate therapy.95 These studies suggest that if MTX 
down-regulates IL-1 production the effect oc­
curs in the early phase of treatment. To test this 
hypothesis, we monitored 26 patients treated 
with methotrexate for 24 weeks. Some decrease 
in IL-1 production occurred after 4 weeks, but 
the effect was not progressive and measure­
ments after 24 weeks were not significantly 
lower than those at baseline.84 Therapy with 
methotrexate did not alter circulating IL-1 (3 
concentrations in this and another study,84»95 but 
decreases in serum96 and in synovial fluid con­
centrations of IL-1(B have been described.97 
Taken together, methotrexate may inhibit the 
proliferative effects of IL-1, and decrease mono­
cyte IL-1 production in the short term in certain 
patients, although this effect is not sustained 
and unlikely explains the long-term efficacy of 
methotrexate. Further investigation is needed 
to elucidate whether therapy with methotrexate 
decreases the production of IL-1 in the joint.
In-vitro, methotrexate inhibits IL-6 but not 
TNF bioactivity86 and decreases the production
of IL-8 by monocytes.39 The synthesis of IL-8 by 
endothelial cells20 or RA synoviocytes38 is not 
affected by the drug. Treatment with methotrex­
ate reduces circulating IL-6,84,96’98*99 IL-8,96 and 
p55 soluble TNF receptor (sTNFR) concentra­
tions98 in patients with RA but does not affect 
circulating levels84,98 or monocyte production of 
TNFa .84’94 Decreases in IL-6, IL-8, and p55 
sTNFR levels probably reflect clinical improve­
ment and are not a specific effect of methotrex­
ate. Several studies have investigated the effects 
of methotrexate on T cell-derived cytokines. In 
vitro this drug enhances the cytotoxic100 and 
proliferative86 effects of IL-2 and the produc­
tion of this cytokine by lymphocytes.101 Metho­
trexate therapy normalizes the defective produc­
tion of IL-2 in the adjuvant and streptococcal 
cell wall arthritis models.91,93 Lymphocyte IL-2 
synthesis increases after a single dose of metho­
trexate in patients with RA102 and in patients 
receiving the drug for longer periods.96,103 Kre- 
mer et al96 reported increases in serum IL-2 
concentrations during treatment with methotrex­
ate,96 and decreases associated with disease 
flares 4 weeks after withholding the drug.104 The 
defective IL-2 production in RA might be due 
to excessive polyamine production,105 which is 
inhibited by methotrexate.106 This effect could 
explain the enhanced IL-2 production observed 
during methotrexate therapy.107 In contrast with 
this up-regulation of IL-2, treatment with metho­
trexate reduces the circulating sIL-2R levels in 
patients with RA84,98,99’108 and juvenile chronic 
arthritis.109 This effect does not predict re­
sponse to treatment108 but rather reflects clini­
cal improvement.98
Recent studies suggest that methotrexate may 
not only upregulate Thl-cytokines, like IL-2, 
but also may downregulate Th2-derived cyto­
kines. Taylor et al110 observed an increased 
mRNA expression of IL-4 and IL-10 in mono­
nuclear cells from RA patients compared with 
healthy controls. Treatment with methotrexate 
reduced IL-4 and IL-10 but enhanced IFN7 
expression in patients with RA.1U) Consistent 
with these effects, Kremer et al96 reported 
decreases in serum IL-4 during methotrexate 
therapy and increases in circulating IL-4 levels 
associated with disease flares after stopping 
treatment.102 The effects of methotrexate on 
IL-2, IL-4, and IL-10 are puzzling because they
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suggest a shift in cytokine expression towards a 
“pro-inflammatory” pattern.
Azathioprine
The purine analogue azathioprine is con­
verted in 6-mercaptopurine (6-MP) which fol­
lows pathways similar to endogenous purines 
and is incorporated into DNA and RNA. The 
cytotoxicity of azathioprine is unlikely to ac­
count for its therapeutic efficacy in RA, but the 
levels of endogenous purine enzymes respon­
sible for its metabolism may influence its toxic­
ity.111
In vitro studies suggest that azathioprine does 
not alter IL-2 production,112,113 whereas both 
azathioprine and 6-MP inhibit IL-6 bioacti­
vity.78 Studies concerning the effect of therapy 
with azathioprine on cytokines in patients with 
RA are scant. In a 48-week trial of azathioprine 
versus methotrexate, we observed no significant 
changes in the circulating concentrations of 
either TNFa or the soluble TNF and IL-2 
receptors during treatment with azathioprine. 
Decreases in IL-6 concentrations reflected clini­
cal improvement and were not specific to the 
drug.98 In a smaller study, Crilly et al114 reported 
no changes in either circulating sIL-2R levels or 
in the production of IL-6 by monocytes after 24 
weeks of azathioprine therapy.
Cyclosporin A
Cyclosporin A is an immunosuppressive agent 
that specifically interferes with T cell activation. 
Complexes of cyclosporin A with its specific 
receptor, cyciophilin, bind to and block the 
activity of calcineurin, preventing the activation 
of transcription factors involved in cytokine 
gene expression.115 The major effect of cyclo­
sporin A is the suppression of T cell activation, 
which is due to inhibition of the transcription 
and synthesis of IL-2 and the expression of 
receptors for IL-2 in lymphocytes.115'116 This 
results in secondary inhibition of B lymphocyte, 
natural killer (NK) cell and macrophage activi­
ties. Besides its effect on IL-2, cyclosporin A 
inhibits the transcription of IL-3, IL-4, IL-5, 
IFN7 ,116 and TNFa117 in T cells. The synthesis 
of IL-1 by monocytes is not affected by cyclo­
sporin A ,23 although the drug may antagonize 
some of this cytokine’s effects in bone and 
cartilage.116 Linder certain conditions, cyclo­
sporin A decreases monocyte TNFa produc­
tion.116-118
Decreases in the number of circulating cells 
bearing the IL-2R119 and in circulating sIL-2R 
and IL-6 concentrations120,121 have been re­
ported in RA patients treated with cyclosporin
A. Decreases in sIL-2R levels associated with 
clinical improvement also have been observed 
during cyclosporin A therapy for Crohn’s dis­
ease122 but not in systemic sclerosis.123
Corticosteroids
Glucocorticoids (GCs) affect virtually every 
cellular and humoral mechanism involved in 
inflammation and immune response, including 
cytokines. The mechanism of action of GCs is 
complex but involves regulation of gene tran­
scription. GCs form complexes with specific 
cytoplasmic receptors, which are translocated 
to the cell nucleus. Interestingly, mononuclear 
cells from patients with RA shown a low GC 
receptor density, although this does not result in 
GC resistance.124 The binding of GC-receptor 
complexes to regulatory elements of DNA re­
sults in either positive or negative regulation of 
gene transcription. GCs interfere with cytokine 
production not only by suppressing their tran­
scription, but also by decreasing messenger 
RNA stability and affecting other posttranscrip- 
tional events.125-128 This inhibits the synthesis of 
proinflammatory and chemotactic cytokines such 
as IL-1, TNFa, IL-6, IL-8, and monocyte chemo­
tactic and activating factor (MCAF), and hemo­
poietic growth factors such as IL-3 and GM- 
CSF.20’38’128'132 In addition, GCs interfere with T 
cell activation by down-regulating the gene 
expression of IL-2 and IL-2R, inhibit the produc­
tion of IL-4 and IFN7 by lymphocytes,133’134 and 
induce IL-1 and IL-6 receptor expression in 
some cells.135-137 In vitro experiments have shown 
that the combination of GCs with IL-4 sup­
presses the synthesis of IL-1 and TNFa by 
monocytes138 and synovial tissue139 synergisti- 
cally, which may find applications in future 
therapies.
Several studies have provided evidence for a 
modulatory role of GC therapy on cytokine 
production or release in vivo. In humans, therapy 
with GCs attenuates the toxicity induced by 
IL-2 and lymphokine activated killer cells, 
OKT3, and experimental endotoxinemia by re­
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ducing the release of TNFa, IFN7 , and IL-2 in 
the circulation.140'142 These drugs inhibit IL-4 
and IL-5 expression by bronchoalveolar cells143 
and monocyte TNF production144 in asthmatic 
patients and reduce circulating IL-6 levels in 
patients with polymyalgia rheumatica and giant 
cell arteritis.145 In RA, circulating levels of IL-6, 
IL-8, and sIL-2R146 and the production of IL-1 
by monocytes147 decrease significantly after pulse 
therapy with high-dose corticosteroids, and re­
ductions in sIL~2R148 and TNFa149 concentra­
tions are associated with improvement during 
treatment with low-dose GCs.
Other Drugs
The number of pharmacological agents with 
potential antirheumatic and cytokine-modulat­
ing activities is too long to be fully enumerated. 
Several drugs used for other indications were 
discovered, by chance, to have antiarthritic 
effects. Among these agents, thalidomide, a 
sedative, and pentoxifylline, a phosphodieste­
rase inhibitor used for peripheral vascular disor­
ders, are worthy of mention because of their 
TNFa-suppressive activities. Thalidomide inhib­
its TNFa production, neutrophil chemotaxis, 
and superoxide generation, but its use in RA 
has been limited because of the drug’s toxic­
ity.150 Pentoxifylline decreases TNFa production 
in vitro and in vivo151 and has anti-inflammatory, 
immunomodulatory, and anti-fibrotic proper­
ties. In an open, 3-month trial, performed in 
patients with severe RA refractory other thera­
pies, additional treatment with pentoxifylline 
resulted in clinical improvement. TNF produc­
tion remained unchanged after 3 days of treat­
ment but was, unfortunately, not measured 
thereafter.152
More selective cytokine inhibitors already 
used in clinical trials for RA include IX 207-887 
and the dual cyclooxygenase/lipoxygenase in­
hibitor tenidap. IX 207-887 inhibits IL-1, IL-6, 
and superoxide production and is effective in 
animal arthritis. A placebo-controlled study in 
RA reported improvement in clinical and labo­
ratory variables in patients treated with IX 
207-887, although adverse reactions were fre­
quent.153 Tenidap inhibits the synthesis of IL-1, 
IL-6, and TNFa by human monocytes and 
rheumatoid synovium154-155 and decreases T cell 
proliferation and IFN7 synthesis.156 Further­
more, the drug inhibits metalloprotease produc­
tion by chondrocytes exposed to IL-1,157 bone 
resorption induced by IL-1 and TNF ,158 and the 
expression of HLA class II antigens in synovio­
cytes exposed to IFN7 .159 Patients with RA 
receiving tenidap show reductions in acute phase 
reaction and circulating IL-6 and sIL-2R concen- 
trations.160-161
Several immunoregulatory agents under cur­
rent investigation for treating autoimmune dis­
eases may affect cytokine production. These 
encompass drugs with immune-enhancing ef­
fects (levamisole, tilomisole and imuthiol) inhibi­
tors of nucleotide synthesis (mycophenolate, 
brequinar, and mizorbine) and immunosuppres­
sive agents (15-deoxyspergualin, leflunomide, 
FK506, and rapamycin).162’163 Leflunomide, an 
isoxazol-derivative currently undergoing clinical 
trials for RA, inhibits lymphokine-dependent T 
and B cell proliferation and decreases IL-1 and 
TNFa induced proliferation of RA synovial 
fibroblasts.164 FK506 and rapamycin are cyclo­
sporin-related drugs that share structural homol­
ogy and the same immunophillin receptor but 
interfere with T cell activation at a different 
level. Like cyclosporin, FK506 decreases the 
activity of calcineurin, is a potent suppressor of 
IL-2 production and receptor expression, and 
inhibits the transcription of various cytokines 
(IL-3, IL-4, IL-5, IFN7 , TNFa , 118 and IL-8165).
Rapamycin interferes with lymphokine signal 
transduction without affecting calcineurin activ­
ity. Both agents are effective in animal arthritis 
and are being evaluated in patients with autoim­
mune diseases and organ allografts.
THERAPY WITH CYTOKINES AND 
ANTICYTOKINES IN RA
Advances in molecular biology have provided 
new therapeutic approaches for autoimmune 
diseases. Among the immunomodulators, se­
lected cytokines such as IFN7 , GM-CSF, and 
G-CSF have been used to treat RA or its 
complications and promising results are being 
obtained with specific antagonists of proinfiam- 
matory cytokines.
The rationale for the use of IFN7 therapy in 
RA was tenuous, being based on the relative 
deficiency of this cytokine in the joint and its 
inhibitory effects on B cells, neutrophils, fibro­
blasts, and cytokine release. The lack of signifi-
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Table 2: Anticytokine Therapies for Rheumatoid Arthritis (1 and 2)
Reference
Compound, 
Study Design
No. of
Patients Dose Schedule
173
174
175
176
177
178
179
180
180
Murine antML-6 
MoAb (BE8) 
Open
Murine anti-IL-2R 
MoAb 
(Campath 6) 
Pilot 
IL-2-diphteria 
fusion toxin
(DAB486)
Open, phase
Dose ranging
Double-blind, 
phase I!
Placebo-con­
trolled (first 
course), fo l­
lowed by 
open study 
IL-2-diphteria 
fusion toxin 
{DA8389)
Open, phase
I/I t
Extension 
study 
Open, phase
Recombinant
IL-IRa
(Anakinra) 
Double-blind, 
phase I 
Placebo-con­
trolled 
Dose ranging 
Open, dose 
ranging 
Double-blind, 
phase II 
Dose and fre­
quency 
ranging
8
3
19
45
20
40
25
15
175
10 mg/day for 10 
days
25 mg/day for 10 
days
75, 130, 260 
kU/kg/dayfor 
5 to 7 days, 
repeated 
courses in 13 
patients 
0,7 mg/kg/day 
for 5 days 
repeated 3 
monthly for up 
to 3 courses
75,150 
kU/kg/dayfor 
5 days
150 kU/kg/day 
for 5 days; 
repeated 
courses by 
flare, up to 4 
courses in 2 
years
0.5, 1,2,4, 6 
mg/kg, single 
dose
Comments
1,2, 4 mg/kg/day 
for 28 days 
20, 70, 200 mg 
per dose; first 3 
weeks: 1, 3, or 
7 dose weekly; 
last 4 weeks: 1 
dose weekly
Improvement transient, mean duration 2 months; 
increased serum IL-6 in 4 patients; antimouse immu­
nization in 2 patients; fever, chills and hypertension 
in 1 patient
Improvement for 3 months in 2 patients, no significant 
side effects reported
Improvement in 9 patients (medium or high dose), 
duration 4-30 weeks, maintained improvement with 
repeated courses, anti-diphteria toxin immunization 
in all patients, very common adverse events (trans­
aminase evaluations)
Improvement in 4/22,11 /36, and 11 /33 patients after 
first, second, and third course respectively; 
anti-DT immunization in all patients, very common 
adverse events
Patients were refractory to- and continued metho­
trexate therapy; improvement in 5/16 patients 
receiving high dose course; common adverse 
events, often transaminase elevations 
Additional methotrexate in 10 patients; lack of effect in 
17 patients, less common adverse events; 
maintained improvement with repeated courses
Improvement in tender joint count in the high-dose 
group
Improvement after 7 days, frequent skin reactions at 
the injection site, 3 patients withdrawn (side effects) 
improvement most marked with daily dose; frequent 
skin reactions at the injection site (62%); 25 patients 
withdrawn (lack of effect [n = 12], adverse events 
[n = 131) multicenter, placebo controlled trial 
ongoing
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Table 2: Anticytokine Therapies for Rheumatoid Arthritis (1 and 2) (Cont'd)
Compound, No. of 
Reference Study Design Patients Dose Schedule Com m ents
181
182
183
184
185
186
187
Recombinant 
slL-1 R type 
Double-blind, 
phase I 
Placebo-con­
trolled 
Dose ranging 
Chimeric anti- 
TNFctMoAb 
(cA2)
Open, phase
Extension
study,
repeated
doses
Double-blind, 
placebo-con­
trolled, dose 
ranging 
Pilot in JCA
Humanized anti- 
TNFce MoAb 
(CDP571) 
Double-blind, 
placebo-con 
trolled, dose 
ranging 
Extension 
study, open
Dimeric p55
sTNFR fusion 
protein 
(R045-2081) 
Double-blind, 
placebo-con­
trolled, dose 
ranging 
Dimeric p75
sTNFR fusion 
protein 
Phase I, pla­
cebo-con­
trolled, dose 
ranging
23
20
8
73
1
36
30
16
125, 250, 500, 
1000
fig/m2/day for 
28 days
Tendency to improve observed in treatment versus 
placebo group, but no patient achieved significant 
improvement few side effects
20 mg/kg divided 
in 2-4 doses
Maximal improvement at 3 weeks, median 14 weeks 
few side effects: minor infections (n -  2), develop- 
during 2 weeks ment of anti-dsDNA (n = 2), and anticardiolipine anti
bodies (n = 1)
Shorter improvement duration after repeated doses? 3 
patients withdrawn (side effects), development of 
antinuclear antibodies {n = 2), increase in anti- 
dsDNA titers (n = 1), antimouse immunization 
(n = 4)
Rapid- and dose-dependent improvement, few side 
effects; increased infections?
Up to 3 additional 
courses of 10 
mg/kg
1,10 mg/kg, one 
dose
Two doses of 10 Unchanged joint symptoms, decreased fever and IL6 
mg/kg levels
0.1,1,10 mg/kg, 
one dose
Improvement at 1-2 weeks in the high dose group, 
dose-dependent response, no significant decrease in 
swollen joints
1,10 mg/kg, 
second dose
0.1, 0.2, 0.4 
mg/kg every 4 
weeks, up to 3 
doses
Best response in the high dose group; 8 patients with 
drawn (disease progression); study with repeated 
doses ongoing, some patients become ANF+ 
Results unpublished, extension study ongoing
Loading dose: 
4-32 mg/m2, 
then mainte­
nance dose: 
2-16 mg/m2 
twice weekly 
for 4 weeks
Some tendency to improvement but no dose response 
observed
Abbreviations: MoAb, monoclonal antibody; IL, interleukin; TNFa, tumor necrosis factor-a; sTNFR, soluble TNF receptor; ANF, 
antinuclear factor.
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cant improvement observed in most studies for 
RA14 is therefore not surprising. Considering 
the powerful immunostimulatory effects of 
IFN7 , disease flares rather than improvement 
could be expected. Induction of antinuclear 
antibodies, and SLE in patients with RA,166'167 
and disease exacerbation in patients with SLE 
may occur during IFN7 therapy,168 and there is 
no indication for using IFN7 in these disorders. 
In contrast, the improvement of skin fibrosis 
and pulmonary function observed in open trials 
with IFN7 for systemic sclerosis169’170 suggests 
that IFN7 may prove useful as antifibrotic 
therapy. The colony-stimulating factors GM- 
CSF and G-CSF improve the granulocytopenia 
associated with Felty’s syndrome as well as that 
induced by antirheumatic and cytostatic thera­
pies, but because these agents may induce 
arthritis flares, their use should be restricted to 
treating or preventing infections associated with 
long-lasting neutropenia.171’172
To date, IL-1, TNF, IL-6, and IL-2 have been 
the target of specific anticytokine approaches in 
RA (Table 2). The experience with anti-IL-2 
and anti-IL-6 treatment is limited,171"178 and 
most attention has been drawn by therapies 
counteracting the two pivotal mediators TNFa 
and IL-1.179"187 Initial results suggest that these 
anticytokine therapies are well tolerated and 
result in rapid improvement of clinical symp­
toms and laboratory parameters. Because these 
effects are transient, repeated administration is 
necessary. Besides the therapies listed in Table 
2, other approaches, including soluble IL-1 
receptors, inhibitors of the specific IL-1 conver- 
tase,16 antiinflammatory cytokines such as IL-4, 
IL-10, and IL-13, and the use of antisense 
oligonucleotides and gene therapy, are under 
investigation.
SUMMARY, CONCLUSIONS, AND FUTURE
PROSPECTS
The search for evidence that antirheumatic 
drugs interfere with cytokines is hampered by 
several problems, not least among those being 
the difficulty in extrapolating experimental data 
obtained in vitro to the situation in vivo (or in 
humans): Some SAARDs alter cytokine produc­
tion or activity only at drug concentrations that 
are not attainable during therapy, and most in
vitro studies do not take into account the effect 
of drug metabolites or the complexity of the 
immune response in vivo. This is exemplified by 
the bimodal effect of gold compounds on IL-1, 
IL-2, and IL-8. Although low concentrations of 
these agents seem to stimulate IL-1 and IL-2 
and inhibit IL-8 production, the converse occurs 
at higher drug concentrations. 19>20»31>52 More­
over, in the case of IL-2, either stimulation or 
strong inhibition can be attained with low con­
centrations of GST depending on the glutathi­
one content of the cells studied.52 In vitro 
results, therefore, need to be confirmed by 
observations in vivo. Experience with animal 
models has taught us about the arthritogenic 
potential of cytokines and the effects of therapy 
with drugs and other anticytokine strategies, but 
the differences between human and animal 
arthritis emphasizes the need for human stud­
ies. Reports on the effects of SAARD therapy 
on cytokines in RA are relatively scarce and 
pitfalls include methodological problems, inter­
individual variations in cytokine concentrations, 
and most importantly, the need to quantify an 
increasing number of cytokines, preferably in 
the joint. Moreover, because SAARDs also 
modify disease activity in RA, changes in cyto­
kine concentrations or expression during therapy 
with these agents may reflect clinical improve­
ment rather than a specific drug effect.
Despite these problems, some conclusions on 
the cytokine-modulating effects of antirheumatic 
drugs can be drawn. First, it seems likely that 
many effects of antirheumatic agents on inflam­
mation and immune response are mediated by, 
or result in, cytokine modulation. Second, the 
effects of antirheumatic drugs are usually not 
confined to a single cytokine. Even cyclosporin, 
considered to downregulate IL-2 gene transcrip­
tion most specifically, also inhibits the synthesis 
of other T cell-derived cytokines,116 whereas 
corticosteroids, have the broadest spectrum of 
activity and inhibit gene transcription of virtu­
ally every cytokine gene. Third, in contrast to 
the usually low levels of IL-1 and TNFa, high 
concentrations of IL-6, sIL-2R, and sTNFR are 
present in the circulation and synovial fluid of 
RA patients, and correlate with several disease 
activity measures. Therapy with a number of 
SAARDs and corticosteroids decreases circulat­
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ing IL-6 and sIL-2R concentrations and sTNFR 
levels apparently decrease with methotrexate 
given alone or in combination with SASP.84’94 
These effects probably reflect clinical improve­
ment and suggest that IL-6, sIL-2R, and sTNFR 
may be useful markers of disease activity in RA. 
Fourth, preliminary evidence suggests that 
therapy with certain SAARDs may regulate 
cytokine production by circulating cells and, 
most importantly, cytokine expression in the 
joint, as recently shown during gold therapy.46
The most important conclusion from previous 
studies is that our knowledge of the effects of 
SAARD therapy on the cytokine network in RA 
is patchy. Properly controlled, longitudinal stud­
ies assessing both cytokine concentrations in 
biological fluids and their expression in the joint 
during SAARD therapy are needed.
The rheumatologists are familiar with the use 
of combinations of NSAIDs, SAARDs, and 
corticosteroids as well as with patients refrac­
tory to these treatments. This has resulted in a 
search for novel therapies aimed at interfering
with specific sites of immunoregulation, inflam­
mation, and tissue destruction. The targets 
envisaged include T cells, antigen presentation, 
adhesion molecules, metalloproteases, nitric ox­
ide, and cytokines. Trials with anticytokine 
therapies have reported rapid but transient 
clinical benefits in RA and ongoing studies will 
show whether these effects can be maintained 
with repeated administration. There is wide 
clinical experience with SAARD therapy for 
RA and it is unlikely that novel therapies will 
supplant these agents in the near future, al­
though combinations of cytokine-suppressive 
and traditional therapies offer interesting per­
spectives. More knowledge on the effect of 
SAARDs on cytokines is needed before we 
arrive at selected combinations that comple­
ment each other’s actions and translate this into 
better treatment for RA.
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